Evofem Biosciences to Report Fourth Quarter and Year-End 2020 Results and Provide Corporate Update on Thursday, March 4, 2021

Rhea-AI Summary

Evofem Biosciences, Inc. (NASDAQ: EVFM) is set to hold a webcast and conference call on March 4, 2021, at 4:30 p.m. ET, to discuss its financial results and business highlights for the fourth quarter and full year ended December 31, 2020. Investors can access the live webcast through the Company’s website or by dialing (866) 503-5561 for U.S. callers. The conference ID is 9928997. Evofem focuses on innovative women’s health solutions, including the hormone-free contraceptive Phexxi®. More details can be found at the company’s website.

SAN DIEGO, Feb. 18, 2021 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) will hold a webcast and conference call to discuss the Company's financial results and business highlights for the fourth quarter and year ended December 31, 2020 as follows:

Date	Thursday, March 4, 2021
Time	4:30 p.m. ET (1:30 p.m. PT)
Webcast (live and archived)	www.evofem.com  under "Investors"
Dial-in numbers	(866) 503-5561 (U.S. toll-free) or (253) 336-2965
Conference ID	9928997

The live webcast and related slide presentation can be accessed through the Investors section of its website or directly at https://evofem.investorroom.com/Q4YE2020Results.  Please connect to the Company's website at least 15 minutes prior to the start of the call to download any software that may be required.

If participating by phone, please dial in approximately 15 minutes prior to the start of the call.

The webcast will be archived at https://evofem.investorroom.com/Q4YE2020Results. A telephone replay will be available for 24 hours after the call at (855) 859-2056 (U.S.) or (404) 537-3406 (International), conference ID 9928997.

About Evofem Biosciences, Inc.
Evofem Biosciences, Inc., (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). The Company's first commercial product, Phexxi^® (lactic acid, citric acid and potassium bitartrate), is the first and only hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy. The Company's lead product candidate, EVO100, is being evaluated for the prevention of urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women in the ongoing Phase 3 clinical trial, 'EVOGUARD.' For more information, please visit www.evofem.com.

Phexxi^® is a registered trademark of Evofem Biosciences, Inc.

Investor Relations Contact
Amy Raskopf
Evofem Biosciences, Inc.
araskopf@evofem.com
Mobile: (917) 673-5775

Media Contact
Ellen Thomas
Evofem Biosciences, Inc.
ethomas@evofem.com 
Mobile: (718) 490-3248

View original content to download multimedia:http://www.prnewswire.com/news-releases/evofem-biosciences-to-report-fourth-quarter-and-year-end-2020-results-and-provide-corporate-update-on-thursday-march-4-2021-301230571.html

SOURCE Evofem Biosciences, Inc.

FAQ

When will Evofem Biosciences report its Q4 and year-end 2020 results?

Evofem Biosciences will report its Q4 and year-end 2020 results on March 4, 2021.

What time is the Evofem Biosciences conference call scheduled for?

The Evofem Biosciences conference call is scheduled for 4:30 p.m. ET on March 4, 2021.

How can I access the Evofem Biosciences webcast?

You can access the Evofem Biosciences webcast through their website or directly via the investors section.

What is the conference ID for the Evofem Biosciences call?

The conference ID for the Evofem Biosciences call is 9928997.

What is the focus of Evofem Biosciences?

Evofem Biosciences focuses on developing innovative products for women's sexual and reproductive health.